Coronado Biosciences Inc. (CNDO) announced that the U.S. Food and Drug Administration or FDA has granted orphan-drug designation to CNDO-109-Activated Allogeneic Natural Killer Cells or CNDO-109 for "the treatment of acute myeloid leukemia or AML."
CNDO-109 is a biologic that activates the immune system's natural killer cells to seek and destroy cancer cells. Preclinical studies of CNDO-109 have demonstrated activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer and, based on data obtained from a Phase 1 investigator-sponsored clinical trial in patients with AML, the Company believes early efficacy was observed.
Coronado said it currently plans to initiate a Phase 1/2 dose escalation trial in AML patients in the second half of 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.